References
- Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–37.
- Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866–75.
- Koopman M, Punt CJ. Chemotherapy, which drugs and when. Eur J Cancer 2009;45(Suppl 1):50–6.
- van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol 2010;21(Suppl 6):vi1–10.
- Mechetner E, Brünner N, Parker RJ. In vitro drug responses in primary and metastatic colorectal cancers. Scand J Gastroenterol 2010;46:70–8.
- Champoux JJ. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I. Ann NY Acad Sci 2000;922:56–64.
- Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722–6.
- Arnould S, Guichard S, Hennebelle I, Cassar G, Bugat R, Canal P. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. Biochem Pharmacol 2002;64:1215–26.
- McLeod HL, Keith WN. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 1996;74:508–12.
- Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther 2009;8:1878–84.
- Reinhold WC, Mergny JL, Liu H, Ryan M, Pfister TD, Kinders R, Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res 2010;70:2191–203.
- Perego P, Capranico G, Supino R, Zunino F. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs 1994;5:645–9.
- Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 1997;70:335–40.
- Yu J, Miller R, Zhang W, Sharma M, Holtschlag V, Watson MA, Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. Pharmacogenomics 2008;9:1459–66.
- Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008;26:2690–8.
- Nielsen HJ. The effect of ranitidine on long-term survival in primary colorectal cancer. A 40 months interim analysis. GI Cancer 1998;2:227–33.
- Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894–904.
- Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–45.
- Jensen KC, Turbin DA, Leung S, Miller MA, Johnson K, Norris B, New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat 2008;112:453–9.
- Boonsong A, Marsh S, Rooney PH, Stevenson DA, Cassidy J, McLeod HL. Characterization of the topoisomerase I locus in human colorectal cancer. Cancer Genet Cytogenet 2000;121:56–60.
- Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003;63:8634–47.